This article is the second of a 4-part series including the following topics: “What is life science,” “Translational Research” (current feature), “Spatial Research,” and “Biomarkers in Translational/Spatial Research.

NEW YORK, NY and VISTA, CALIF. – April 23, 2021 — Paige, a global leader in AI-based digital diagnostics, and Leica Biosystems, a globally recognized cancer diagnostics and workflow solution leader, today announced a strategic partnership to expand access to computational pathology products for clinical and translational research. The partnership brings Paige’s AI-enabled research software for tumor detection, grading and quantification to Leica Biosystems digital pathology platform in select countries throughout North America and Europe. The companies will collaborate to streamline and accelerate research workflows in pathology and oncology for higher quality, improved consistency and faster throughput. Leica Biosystems will distribute Paige’s research-use-only ...

Research-use-only RNA-ISH probes now available for COVID-19 on our automated platform Leica Biosystems, in partnership with Bio-Techne Corporation, announces the automation of RNAscope™ COVID-19 probes’ on BOND RX*, its staining platform, for research use only. Researchers now have the capability to automate their COVID-19 research protocols, reducing manual labor and turnaround time. “We expect the automation of COVID-19 research protocols on BOND RX to enable researchers to achieve breakthroughs faster in their research for vaccines, treatment or other vital areas of investigation,” said Melissa Aquino, President, Leica Biosystems. “The partnership with Bio-Techne has enabled us to offer RNAscope COVID-19 probes to our BOND RX customers, which is an example of our commitment ...

CAMBRIDGE, MASS., JANUARY 31, 2022. Companion diagnostic supports patient identification and enrollment into clinical trials of Leap Therapeutics‘ DKK1 inhibitor, DKN-01 Leica Biosystems, a cancer diagnostics company, has entered into an agreement with Leap Therapeutics (Nasdaq: LPTX), a biotechnology company, to develop a companion diagnostic to detect Dickkopfrelated protein 1 (DKK1). The assay will be used to support the clinical development of Leap Therapeutics’ anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. DKK1 is a protein often implicated in cancer, enabling tumor cells to suppress the immune system and lead to unregulated growth. Overexpression of DKK1 is associated with poor survival in cancer patients. Leap Therapeutics is currently ...

Incorporation and Automation of RNAscope Technology into your COVID-19 Viral Pathogenesis Research. Research Use Only, Not for Clinical Diagnostic Procedure For Research Use Only. Not For Diagnostic Use. Incorporation of the highly sensitive and specific RNAscope technology into your COVID-19 Viral Pathogenesis Research Jyoti Sheldon Applications Research Use Only, Not for Clinical Diagnostic Procedure Agenda RNAscope technology overview COVID-19 Offerings COVID-19 Publications Research Use Only, Not for Clinical Diagnostic Procedure RNAscope®In Situ Hybridization (ISH) Technology A hybridization-based signal amplification system with a unique probe design - Simultaneous signal amplification and background suppression Amplification Target-specific binding A specific and sensit...

Grant writing is a critical part of an investigator’s portfolio. Download this helpful resource for tips and tricks on how to write a grant proposal.

VISTA, CA – Aug 9, 2019 – Leica Biosystems, the global leader in pathology workflow solutions, announced today that it has launched the Aperio GT 450, its next generation digital pathology scanner. The Aperio GT 450, labeled as research use only, offers continuous rack loading with priority scanning and takes only 32 seconds to scan a 15mm by 15mm tissue area on a pathology slide at 40x magnification with throughput of 81 slides/hr. This new technology allows customers performing research to scale up digital pathology to meet ever increasing slide volume demands. “The Aperio GT 450 has demonstrated, in a workflow study at our laboratories, substantial increases in throughput while dramatically reducing hands on time for our histotechnicians. This frees up additional FTE capacit...

Imagine the possibilities for your Chromogenic Multiplex with Leica Biosystems and Cell IDx To accelerate the discovery journey in cancer research, Leica Biosystems has partnered with Cell IDx, a technology leader in multiplexed cellular immunodiagnostics, developing highly sensitive and specific reagents for research and clinical immunohistochemistry to meet the needs of precision medicine. Cell IDx technology allows the automated detection of multiple markers on the BOND RX staining system. The technology uses primary antibodies from any species, employing a single antigen retrieval step that allows detection of three chromogen stains in 4.5 hours and four chromogen stains in 6 hours. The process is simple, fast, and fully automated on the BOND RX platform and Aperio Brightfi...

SEATTLE, USA and MELBOURNE, AUSTRALIA. March 1st Leica Biosystems continues to advance its relationship with NanoString Technologies Inc., supporting translational research to build confidence in reproducibility and throughput while minimizing manual steps and reducing hands-on time with the release of the fully automated GeoMx RNA protocol on BOND RX and BOND RXm research staining systems. “This fully automated protocol not only increased our ability to get more slides done in a week but also increased the quality of the data coming off of our instrument by reducing variability between runs,” said Carlee Hemphill, lead scientist, CDx Labcorp Drug Development. NanoString's GeoMx Digital Spatial Profiler uses spatial images, chemistry, and workflow to enable high-plex profiling ...